Intermediate hepatocellular carcinoma (BCLC B)
Intermediate hepatocellular carcinoma is several tumours inside a working liver, too many to cut out but with no spread beyond it. The standard treatment for two decades has been chemoembolisation through the hepatic artery, and trials now show that adding immunotherapy and anti-angiogenic drugs to it delays progression.
Overview
BCLC stage B covers multinodular hepatocellular carcinoma with preserved liver function, no cancer-related symptoms and no macrovascular invasion or extrahepatic spread. The 2022 BCLC update split it into three groups: patients whose tumour burden allows downstaging or extended transplant criteria, those with well-defined nodules suited to transarterial chemoembolisation, and those with diffuse, infiltrative or bilobar disease who do better moving straight to systemic therapy, a change described as treatment stage migration.
Transarterial chemoembolisation delivers chemotherapy-loaded particles or drug-eluting beads into the arteries feeding the tumours and blocks them; two randomised trials in 2002 (Llovet in Barcelona and Lo in Hong Kong) showed it prolongs survival, and it has been the standard since. Radioembolisation with yttrium-90 microspheres is an alternative with fewer post-procedure symptoms, though phase 3 trials against sorafenib in more advanced disease were negative. Repeated embolisation damages the liver, so the ART and other scores guide when to stop and switch.
Two phase 3 trials published in the Lancet in 2025 added systemic therapy to chemoembolisation: EMERALD-1 combined durvalumab and bevacizumab with TACE and extended median progression-free survival from 8.2 to 15.0 months, and LEAP-012 combined lenvatinib and pembrolizumab with TACE and extended it from 10.0 to 14.6 months; overall survival was immature in both at first analysis. EMERALD-3, testing durvalumab and tremelimumab with TACE, reported a benefit in 2026. The atezolizumab-bevacizumab and other advanced-stage regimens are also used directly in patients with high tumour burden, and ongoing trials compare systemic therapy alone with the combinations.
State of the art
- Chemoembolisation remains the backbone, but the 2022 BCLC update sends patients with diffuse or high-burden disease straight to systemic therapy.
- EMERALD-1 and LEAP-012 are the first phase 3 trials to improve on TACE alone in twenty years.
- Whether the combinations lengthen life, not just time to progression, is still awaited.
Anatomy and lymph node drainage
- Right lobe (segments V-VIII)
- Left lobe (segments II-IV)
- Portal vein (macrovascular invasion)
- Capsule and diaphragm surface
- Nodes: hepatic hilar
- Nodes: coeliac
- Nodes: paracaval
Hepatocellular carcinoma grows in a cirrhotic liver and spreads first inside it and into the portal vein, so staging depends on liver function and vascular invasion as much as on size.
- Right lobe (segments V-VIII)Multinodular HCC in a cirrhotic liver within the up-to-seven criteria (downstaging or extended transplant)
- Left lobe (segments II-IV)
- Portal vein (macrovascular invasion)
- Capsule and diaphragm surface
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Multiple tumours confined to a liver that still functions, without vein invasion or spread; the most heterogeneous BCLC stage, for which the 2022 update expects a median survival above two and a half years with chemoembolisation and now systemic therapy.
Transarterial chemoembolisation, conventional or with drug-eluting beads, repeated on demand; radioembolisation as an alternative.
Durvalumab with bevacizumab (EMERALD-1) or lenvatinib with pembrolizumab (LEAP-012) added to TACE, where approved; durvalumab-tremelimumab with TACE after EMERALD-3.
Systemic therapy as for advanced disease (atezolizumab-bevacizumab or durvalumab-tremelimumab) instead of embolisation.
Chemoembolisation or radioembolisation as a bridge, then liver transplantation.
Subtypes & biomarkers
top- Multinodular HCC in a cirrhotic liver within the up-to-seven criteria (downstaging or extended transplant)
- Well-defined nodules suitable for TACE
- Diffuse or infiltrative bilobar HCC (systemic therapy first)
- TACE-refractory HCC
- BCLC B treated with TACE plus systemic therapy (EMERALD-1, LEAP-012)
- Tumour number and size (up-to-seven and other burden criteria)
- Child-Pugh and ALBI liver function before and after each embolisation
- Alpha-fetoprotein response
- Modified RECIST response on contrast imaging
- Absence of macrovascular invasion and extrahepatic spread (defines the stage)
How often this target appears
- 2002Llovet and Lo randomised trials: chemoembolisation prolongs survival
- 2010Drug-eluting bead TACE (PRECISION V) matches conventional TACE with less toxicity
- 2022BCLC update subdivides intermediate stage and introduces treatment stage migration
- 2025EMERALD-1 and LEAP-012: systemic therapy plus TACE delays progression
- 2026EMERALD-3: durvalumab-tremelimumab plus TACE reported positive
Dated changes read from the records linked to this indication: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 6 changes by month →- 2026-09-17This recordIntermediate hepatocellular carcinoma (BCLC B)Facts on this page last checked
When this page itself was last checked or edited.
- 2026MilestoneIntermediate hepatocellular carcinoma (BCLC B)EMERALD-3: durvalumab-tremelimumab plus TACE reported positive
A milestone in how this cancer is treated.
- 2025MilestoneIntermediate hepatocellular carcinoma (BCLC B)EMERALD-1 and LEAP-012: systemic therapy plus TACE delays progression
A milestone in how this cancer is treated.
- 2022MilestoneIntermediate hepatocellular carcinoma (BCLC B)BCLC update subdivides intermediate stage and introduces treatment stage migration
A milestone in how this cancer is treated.
- 2010MilestoneIntermediate hepatocellular carcinoma (BCLC B)Drug-eluting bead TACE (PRECISION V) matches conventional TACE with less toxicity
A milestone in how this cancer is treated.
- 2002MilestoneIntermediate hepatocellular carcinoma (BCLC B)Llovet and Lo randomised trials: chemoembolisation prolongs survival
A milestone in how this cancer is treated.
What is in development for Intermediate hepatocellular carcinoma (BCLC B), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Combinations being explored · 1
Open problems and what is being done
No overall survival gain yet shown for TACE combinations.
Which patients should skip embolisation and go straight to systemic therapy.
Liver damage from repeated embolisation limits later treatment options.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Direct links plus the targets, companies, and technologies of this cancer's products.
isotopes
2fronts
1technologies
1drugs
2companies
3pairings
1Latest papers
topQuery for this indication: (TITLE:"Intermediate hepatocellular carcinoma" OR ABSTRACT:"Intermediate hepatocellular carcinoma" OR TITLE:"BCLC B" OR ABSTRACT:"BCLC B" OR TITLE:"Intermediate-stage HCC" OR ABSTRACT:"Intermediate-stage HCC" OR TITLE:"Multinodular HCC" OR ABSTRACT:"Multinodular HCC" OR TITLE:"TACE-eligible hepatocellular carcinoma" OR ABSTRACT:"TACE-eligible hepatocellular carcinoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Intermediate hepatocellular carcinoma (BCLC B), not a curated reading list.
Similar pages
not linked directly; found by shared links- IndicationNeuroendocrine and small-cell prostate cancer
Shares Pembrolizumab and the tag subtype-page.
- IndicationMetastatic castration-resistant prostate cancer
Shares Pembrolizumab and the tag subtype-page.
- CompanySirtex Medical
Shares Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma, Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- TrialSARAH and SIRveNIB
Shares Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- AgentHolmium-166 microspheres
Shares Holmium-166, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Quirem Medical, Hepatocellular carcinoma, Yttrium-90.
- IndicationPancreatic neuroendocrine tumours
Shares Radioembolisation (TARE / SIRT, yttrium-90) and the tag subtype-page.
- IndicationSmall intestinal neuroendocrine tumours
Shares Radioembolisation (TARE / SIRT, yttrium-90) and the tag subtype-page.